About Us
Nanophysics & Beyond
Curadigm
The Management
Our Commitments
Healthcare Professionals
Scientific Publications
Patients
Patient Engagement
Investors
Corporate Presentation
Financial Calendar
Regulated Information
SEC Filings
Annual General Meetings
Shareholder Corner
Press Releases
Congresses & Events
Nanotalks
NBTXR3 Development
R&D Day
Our Expert Videos
Nanoblog
From Curie to Nano
Contact & Newsletter
Medical Device Vigilance – Pharmacovigilance
Medical Information
Join Us
Nous vous informons que ce site est conforme à la législation française actuelle sur les dispositifs médicaux.
Continuer
Rester sur la page
Scientific Clinical | Nanobiotix partners with the Providence Cancer Institute to run immunotherapeutic preclinical research in pancreatic cancers
Corporate | Nanobiotix: 2017 review and 2018 expected milestones
26 December 2017
Scientific Clinical | Nanobiotix presents first promising data from Phase I/II Liver Cancers trial of NBTXR3 at American Society Of Clinical Oncology Gastrointestinal Annual Meeting
22 January 2018
Scientific Clinical | Nanobiotix partners with the Providence Cancer Institute to run immunotherapeutic preclinical research in pancreatic cancers
Published by
adminvl
on
11 January 2018
No translations available for this page
